ACELYRIN, INC. (SLRN)
(Delayed Data from NSDQ)
$4.62 USD
+0.25 (5.72%)
Updated May 7, 2024 04:00 PM ET
After-Market: $4.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
ACELYRIN, INC. [SLRN]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
4Q23 Recap: Second HS Phase 3 Study and Uveitis Phase 2b/3 Topline Data Guided to 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
Lonigutamab Demonstrates Positive POC For Subcutaneous Dosing in TED
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
Izokibep Phase 2b/3 PsA Study Demonstrates Competitive Efficacy; Week 32 HS Data Show Improvement Overtime
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
Dosing Error Noted in Two Cohorts in the PsA Phase 2b/3 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SLRN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Focus Is on Phase 2b/3 PsA Topline Data and Loni Phase 1b/2 TED Data in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
We Remain Confident in Izokibep PsA Data in 1Q24 at the 160 mg QW/Q2W Dose
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
Izokibep Doesn''t Meet Primary Endpoint in HS Though We Believe Results Were Confounded
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: ACELYRIN, INC.
Industry: Medical - Biomedical and Genetics
|